Table 1.
Patient characteristics
| Characteristic | Patients with TMA in Kidney Allograft (n=8) | Patients with TMA in Diseased Native Kidney (n=28) | All TMA (n=36) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Recurrent aHUS (n=3) | Drug Toxicity (n=2) | Rejection (n=3) | aHUS (n=11) | STEC-HUS (n=1) | SLE/APS (n=8) | HSCT-TMA (n=6) | IgAN (n=1) | AAV (n=1) | ||
| Age at time of first renal sampling (yr) | 34.8 (6.4–37.2) | 43.4 (40.0–46.9) | 66.4 (31.6–72.0) | 46.0 (22.4–77.2) | 13.5 (NA) | 29.5 (16.6–49.4) | 37.7 (17.5–54.2) | 32.1 (NA) | 35.3 (NA) | 37.7 (6.4–77.2) |
| Women | 1 (33.3) | 2 (100.0) | 2 (66.7) | 9 (81.8) | 0 (0.0) | 8 (100.0) | 3 (50.0) | 0 (0.0) | 0 (0.0) | 25 (69.4) |
| Neurologic symptoms | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (27.3) | 0 (0.0) | 3 (37.5) | 3 (50.0) | 0 (0.0) | 1 (100.0) | 10 (27.8) |
| History of malignant hypertension | 1 (33.3) | 0 (0.0) | 0 (0.0) | 1 (9.1) | 0 (0.0) | 0 (0.0) | 1 (16.7) | 0 (0.0) | 1 (100.0) | 4 (9.5) |
| Renal tissue samples | 6 (100.0) | 2 (100.0) | 4 (100.0) | 11 (100.0) | 1 (100.0) | 10 (100.0) | 6 (100.0) | 1 (100.0) | 1 (100.0) | 42 (100.0) |
| Biopsy | 5 (83.3) | 2 (100.0) | 4 (100.0) | 6 (54.5) | 1 (100.0) | 8 (80.0) | 2 (33.3) | 1 (100.0) | 1 (100.0) | 30 (71.4) |
| Autopsy | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (45.5) | 0 (0.0) | 2 (20.0) | 4 (66.7) | 0 (0.0) | 0 (0.0) | 11 (26.2) |
| Nephrectomy | 1 (16.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.4) |
Age is expressed as median (range); all other values are expressed as number (percentage). Drug toxicity refers to TMA in renal allograft in cases caused by toxicity of immunosuppressive therapeutics. Rejection refers to TMA in renal allograft cases during a rejection episode. APS, antiphospholipid syndrome; IgAN, IgA nephropathy; AAV, ANCA-associated vasculitis; NA, not applicable.